Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.46 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.46 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.46 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.42 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.42 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.42 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.42 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.42 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6944593 | 1.00 | POLB (0.46) | POLBPDK1PDK2PDK3PDK4 | |
| SCHEMBL2175331 | 1.00 | POLB (0.46) | POLBPDK1PDK2PDK3PDK4 | |
| SCHEMBL7347136 | 1.00 | POLB (0.46) | POLBPDK1PDK2PDK3PDK4 | |
| SCHEMBL13387830 | 0.92 | POLB (0.45) | POLBPDK1PDK2PDK3PDK4 | |
| SCHEMBL12234850 | 0.92 | POLB (0.48) | POLBPDK1PDK2PDK3PDK4 | |
| SCHEMBL13379347 | 0.91 | PDK1 (0.47) | POLBPDK1PDK2PDK3PDK4 | |
| SCHEMBL23364628 | 0.90 | POLB (0.46) | POLBPDK1PDK2PDK3PDK4 | |
| SCHEMBL13388734 | 0.90 | POLB (0.44) | POLBPDK1PDK2PDK3PDK4 | |
| SCHEMBL17124819 | 0.90 | POLB (0.46) | POLBPDK1PDK2PDK3PDK4 | |
| SCHEMBL6936752 | 0.89 | POLB (0.50) | POLBPDK1PDK2PDK3PDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2519506-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2012-11-07 | — | — | EP | disclosed |
| WO-2011082077-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-07-07 | — | — | WO | disclosed |
| US-7678782-B2 | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs | XENOPORT, INC. (US) | 2010-03-16 | — | — | US | disclosed |
| US-20070015716-A1 | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs | XENOPORT, INC. | 2007-01-18 | — | — | US | disclosed |
| US-7144877-B2 | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs | XENOPORT, INC. (US) | 2006-12-05 | — | — | US | disclosed |
| EP-1358200-A4 | BILE-ACID DERIVED COMPOUNDS FOR ENHANCING ORAL ABSORPTION AND SYSTEMIC BIOAVAILABILITY OF DRUGS | XENOPORT INC (US) | 2005-07-20 | — | — | EP | disclosed |
| EP-1358200-A2 | BILE-ACID DERIVED COMPOUNDS FOR ENHANCING ORAL ABSORPTION AND SYSTEMIC BIOAVAILABILITY OF DRUGS | Xenoport, Inc. (US) | 2003-11-05 | — | — | EP | disclosed |
| US-20020099041-A1 | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs | XENOPORT, INC. | 2002-07-25 | — | — | US | disclosed |
| WO-2002044324-A2 | BILE-ACID DERIVED COMPOUNDS FOR ENHANCING ORAL ABSORPTION AND SYSTEMIC BIOAVAILABILITY OF DRUGS | XENOPORT, INC. (US) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015716-A1 | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs | SLC10A2, ABCB11, SLC10A1 | POLB 3048/4885PDK1 3588/4885PDK2 3770/4885 |
| US-20020099041-A1 | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs | SLC10A2, ABCB11, SLC10A1 | POLB 3048/4885PDK1 3588/4885PDK2 3770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.